同期放化疗与序贯放化疗治疗诱导化疗无效局限期NSCLC患者的疗效比较

[目的]探讨同期放化疗与序贯放化疗对诱导化疗无效的局限期非小细胞肺癌(NSCLC)患者无进展生存期的影响.[方法]本院收治的108例诱导化疗无效的局限期NSCLC患者随机分为两组,每组54例.A组给予同期放化疗,B组给予序贯放化疗,比较两组患者的不良反应发生率、近期治疗效果、中位生存期以及治疗三个周期后的生活质量评分等参数指标.[结果]①A组疗效远远高于B组(P＜0.05);②A组患者中位无进展生存时间显著高于B组(P＜0.05);③A组不良反应发生率显著低于B组(P＜0.05);④治疗前,两组患者的生活质量评分比较差异无显著性(P＞0.05);治疗三个周期后,A组患者的生活质量评分显著高于B组(P＜0.05).[结论]同期放化疗能够显著延长诱导化疗无效的局限期NSCLC患者的生存时间,不良反应较少且显著提高患者生活质量.

Effects of Concurrent Chemoradiotherapy and Sequential Radiotherapy and Chemotherapy on Progression-free Survival in Patients with Non-small Cell Lung Cancer

[Objective]To analyze the effect of concurrent chemoradiotherapy and sequential chemoradiotherapy on progression free survival in patients with limited Non-small-cell Carcinoma (NSCLC) induced by chemotherapy.[Methods]One hundred and eight patients with NSCLC in our hospital were selected as the research object,the patients were randomly divided into group A and group B,each group with 54 cases.The group A received concurrent chemotherapy,the group B was treated with sequential chemotherapy.The adverse reaction rate,the therapeutic effect,the median survival after three cycles of treatment and quality of life score index were compared with between the two groups of patients.[Results]1.The curative effect of the group A was much higher than that of the group B (P ＜0.05);2.The median progression free survival in group A was significantly higher than that in group B (P ＜0.05);3.The incidence of adverse reactions in the group A was significantly lower than that in the group B (P ＜0.05);4.Before treatment,there was no significant difference in quality of life between the two groups (P ＞0.05).After the treatment of the three cycle,the quality of life score of the group A was significantly higher than that of the group B (P ＜0.05).[Conclusion]Concurrent chemoradiotherapy can significantly improve the quality of life of patients with NSCLC,which has less adverse reactions and higher quality of life scores.